MIAMI, FL & SAN DIEGO, CA – September 14, 2023 – Miami Cancer Institute, part of Baptist Health South Florida, today announced its oral and poster presentations at the American Society for Radiation Oncology (ASTRO) Annual Meeting, October 1-5, 2023, at the Convention Center in San Diego, California. The presentations focus on radiation therapy for pancreatic cancer, radiosurgery of brain metastases, proton therapy for osteosarcoma, and the challenges of radiotherapy and radiosurgery in low- and middle-income countries, among many others.

“We could not be more excited about the volume and caliber of radiation-oncology research my Miami Cancer Institute colleagues and I will be presenting at the 2023 ASTRO annual meeting,” said Minesh P. Mehta, M.D., deputy director and chief of radiation oncology at Miami Cancer Institute. “This year, we’re discussing the latest developments in hard-to-treat cancers and conditions, including pancreatic, lung, and head and neck cancers, as well as brain metastases. These are areas of high unmet patient need, and our presentations illustrate our commitment to finding promising and effective avenues for treatment.”

Miami Cancer Institute researchers will give two oral and 12 poster presentations, and host one educational session at ASTRO 2023:

Oral Presentation

**Sunday, October 1, 2023**
Patterns of locoregional failure after ablative 5-fraction stereotactic MR-guided on-table adaptive radiation therapy for pancreatic cancer  
*Speaker:* Michael Chuong, M.D.  
*Time:* 5:35 p.m. PT  
*Location:* Room 1

**Monday, October 2, 2023**
Heatmaps to Assess Tumor Motion Probability with MRcine in Head and Neck Cancer  
*Speaker:* Yonatan Weiss, M.D.  
*Time:* 5:10 p.m. PT  
*Location:* Room 1

**Poster Presentations**

**Monday, October 2, 2023**
Characterization of Large Brain Metastases with 18F-Fluciclovine PET/CT Treated with Staged Stereotactic Radiosurgery (SSRS): Phase 1 Proof-of-Concept Interim Analysis
Presenter: Rupesh Kotecha, M.D.
Time: 10:45 a.m. – 12:00 p.m. PT
Location: Hall B1
Number: 2259

Surgically Targeted Radiation Therapy (STaRT) for Brain Metastases: Initial Experience from a Prospective Multi-Institutional Registry
Presenter: Rupesh Kotecha, M.D.
Time: 10:45 a.m. – 12:00 p.m. PT
Location: Hall B1
Number: 2260

A Comparison of Local Failure and Necrosis Following Different Radiosurgery Strategies for Large Brain Metastases
Presenter: Tugce Kutuk, M.D.
Time: 10:45 a.m. – 12:00 p.m. PT
Location: Hall B2
Number: 2263

Stereotactic Radiosurgery for Small Intact Brain Metastasis: A Comparative Evaluation of 3 Different Single Fraction Prescription Doses
Presenter: Sreenija Yarlagadda, M.D.
Time: 10:45 a.m. – 12:00 p.m. PT
Location: Hall B2
Number: 2304

Dosimetric Evaluation of a Novel Non-Metallic Dual Port Expander for Proton Therapy
Presenter: Andrew Wroe, Ph.D.
Time: 3:00 p.m. – 4:00 p.m. PT
Location: Hall B2
Number: 2455

Tuesday, October 3, 2023
Phase II Trial of Stereotactic MR-Guided On-Table Adaptive Radiation Therapy for Borderline or Locally Advanced Pancreatic Cancer: Updated Safety and Efficacy Outcomes
Presenter: Michael Chuong, M.D.
Time: 12:45 – 2:00 p.m. PT
Location: Hall B1
Number: 2631

Ablative 5-Fraction CT vs. MR-Guided Pancreatic SBRT: Evaluation of Interfraction Anatomic Changes on Dosimetric Constraints
Multi-Institutional Experience of Proton Therapy for Osteosarcoma in the Proton Collaborative Group (PCG) Prospective Registry
Presenter: Keitrina Mair, M.S., B.S.
Time: 12:45 – 2:00 p.m. PT
Location: Hall B2
Number: 2704

The Anatomy and Evolution of a Quality Proton Therapy Plan Check Process: An Institutional Review
Presenter: Andrew Wroe, Ph.D.
Time: 2:30 p.m. – 3:45 p.m. PT
Location: Hall B2
Number: 2909

Integration of an App-based Cognitive Evaluation Program into Radiosurgery Practice: Outcomes and Patient Survey Analysis from a Prospective Observational Study
Presenter: Tugce Kutuk, M.D.
Time: 4:00 p.m. – 5:00 p.m. PT
Location: Hall B2
Number: 3030

Multi-Institutional Experience of Proton Therapy for Rhabdomyosarcoma and Ewing Sarcoma in the Proton Collaborative Group (PCG) Prospective Registry
Presenter: Katherine von Werne, MSN
Time: 5:15 p.m. – 6:15 p.m. PT
Location: Hall B2
Number: 3206

**Wednesday, October 4, 2023**
Retrospective Assessment of Surface Imaging Set up Accuracy for Intensity Modulated Proton Therapy of Comprehensive Breast Irradiation
Presenter: Andrew Wroe, Ph.D.
Time: 12:30 p.m. – 1:45 p.m. PT
Location: Hall B2
Number: 3615

**Educational Session**

**Sunday, October 1, 2023**
Implementation Challenges of Stereotactic Body Radiotherapy and Radiosurgery in Low and Middle Income Countries

Speaker: Minesh Mehta, M.D., M.B., Ch.B., FASTRO
Time: 5:23 p.m. – 5:35 p.m. PT
Location: Room 5

For updates from the ASTRO 2023 Annual Meeting, look for #ASTRO2023 on social media and follow Miami Cancer Institute on Twitter (X) at @MiamiCancerInst.

In addition to the on-site presentations at ASTRO 2023, Miami Cancer Institute’s Michael D. Chuong, M.D., is available for interviews on a novel planning technique for online adaptive radiotherapy in pancreatic cancer patients that was recently published in Radiotherapy & Oncology. The study showed the feasibility toward utilizing a patient-independent, template on-table adaptive approach. This work may impact industry-wide international standards on adaptive radiotherapy currently being considered.

About Miami Cancer Institute
Miami Cancer Institute brings to South Florida access to personalized clinical treatments and comprehensive support services delivered with unparalleled compassion. No other cancer program in the region has the combination of cancer-fighting expertise and advanced technology—including the first proton therapy center in South Florida, Latin America and the Caribbean, and one of the only radiation oncology programs in the world with each of the newest radiation therapies in one place—to diagnose and deliver precise cancer treatments that achieve the best outcomes and improve the lives of cancer patients. The Institute offers an impressive roster of established community oncologists and renowned experts, clinical researchers and genomic scientists recruited from the nation’s top cancer centers. Selected as Florida’s only member of the Memorial Sloan Kettering Cancer (MSK) Alliance, Miami Cancer Institute is part of a meaningful clinical collaboration that affords patients in South Florida access to innovative treatments and ensures that the standards of care developed by their multidisciplinary disease management teams match those at MSK. For more information, please visit https://cancer.baptisthealth.net/miami-cancer-institute.

Miami Cancer Institute is part of Baptist Health Cancer Care, the largest cancer program in South Florida, with locations from the Florida Keys to the Palm Beaches.

###